Lyngbyastatin 2 and norlyngbyastatin 2, analogues of dolastatin G and nordolastatin G from the marine cyanobacterium Lyngbya majuscula

Journal of Natural Products

Volumn 62, Issue 12, 1999, Pages 1702-1706

  Luesch, Hendrik ^a   Yoshida, Wesley Y ^a   Moore, Richard E ^a   Paul, Valerie J ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF GUAM MARINE LABORATORY   (Guam)

Author keywords

[No Author keywords available]

Indexed keywords

DOLASTATIN; LYNGBYASTATIN 2; NORDOLASTATIN; NORLYNGBYASTATIN 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHROMATOGRAPHY; CYANOBACTERIUM; CYTOTOXICITY; DRUG ISOLATION; HARE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CYANOBACTERIA; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MODELS, CHEMICAL; PEPTIDES, CYCLIC; TUMOR CELLS, CULTURED;

EID: 0033428031     PISSN: 01633864     EISSN: None     Source Type: Journal    
DOI: 10.1021/np990310z     Document Type: Article

References (24)

1. (a) Pettit, G. R.; Kamano, Y.; Herald, C. L.; Fujii, Y.; Kizu, H.; Boyd, M. R.; Boettner, F. E.; Doubek, D. L.; Schmidt, J. M.; Chapuis, J.-C.; Michel, C. Tetrahedron 1993, 49, 9151-9170.
2. (b) Pettit, G. R. In Progress in the Chemistry of Organic Natural Products; Herz, W., Kirby, G. W., Moore, R. E., Steglich, W., Tamm, C., Eds.; Springer-Verlag: New York, 1997; Vol. 70, pp 1-79.
3. (c) Pettit, G. R.; Xu, J.-P.; Hogan, F.; Williams, M. D.; Doubek, D. L.; Schmidt, J. M.; Cerny, R. L.; Boyd, M. R. J. Nat. Prod. 1997, 60, 752-754.
4. (d) Pettit, G. R., Xu, J.-P.; Hogan, F.; Cerny, R. L. Heterocycles 1998, 47, 491-496.
5. (e) Pettit, G. R.; Xu, J.-P.; Williams, M. D.; Hogan, F.; Schmidt J. M.; Cerny, R. L. Bioorg. Med. Chem. Lett. 1997, 7, 827-832.
6. (a) Sone, H.; Nemoto, T.; Qjika, M.; Yamada, K. Tetrahedron Lett. 1993, 34, 8445-8448.
7. (b) Sone, H.; Nemoto, T.; Ishiwata, H.; Ojika, M.; Yamada, K. Tetrahedron Lett. 1993, 34, 8449-8452.
8. (c) Ojika, M.; Nemoto, T.; Nakamura, M.; Yamada, K. Tetrahedron Lett. 1995, 36, 5057-5058.
9. (d) Mutou, T.; Kondo, T.; Ojika, M.; Yamada, K. J. Org. Chem. 1996, 61, 6340-6345.
10. (e) Sone, H.; Shibata, T.; Fujita, T.; Ojika, M.; Yamada, K. J. Am. Chem. Soc. 1996, 118, 1874-1880.
11. Harrigan, G. G.; Yoshida, W. Y.; Moore, R. E.; Nagle, D. G.; Park, P. U.; Biggs, J.; Paul, V. J.; Mooberry, S. L.; Corbett, T. H.; Valeriote, F. A. J. Nat. Prod. 1998, 61, 1221-1225.
12. (a) Pennings, S. C.; Paul, V. J. Ecology 1992, 73, 1606-1619.
13. (b) Pennings, S. C.; Paul, V. J. Mar. Biol. 1993, 117, 535-546.
14. Harrigan, G. G.; Luesch, H.; Yoshida, W. Y.; Moore, R. E.; Nagle, D. G.; Paul, V. J.; Mooberry, S. L.; Corbett, T. H.; Valeriote, F. A. J. Nat. Prod. 1998, 61, 1075-1077.
15. Harrigan, G. G.; Luesch, H.; Yoshida, W. Y.; Moore, R. E.; Nagle, D. G.; Paul, V. J. J. Nat. Prod. 1999, 62, 655-658.
16. (a) Corbett, T. H.; Valeriote, F. A.; Polin, L.; Panchapor, C.; Pugh, S.; White, K.; Lowichik, N.; Knight, J.; Bissery, M.-C.; Wozniak, A.; LoRusso, P.; Biernat, L.; Polin, D.; Knight, L.; Biggar, S.; Looney, D.; Demchik, L.; Jones, J.; Jones, L.; Blair, S.; Palmer, K.; Essenmacher, S.; Lisow, L.; Mattes, K. C.; Cavanaugh, P. F.; Rake, J. B.; Baker, L. In Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, Valeriote, F. A., Corbett, T. H., Baker, L. H., Eds.; Kluwer Academic Publishers: Norwell, 1992; pp 35-87.
17. (b) Valeriote, F. A.; Moore, R. E.; Patterson, G. M. L.; Paul, V. J.; Scheuer, P. J.; Corbett, T. In Anticancer Drug Discovery and Development: Natural Products and New Molecular Models, Valeriote, F. A., Corbett, T. H., and Baker, L. H., Eds.; Kluwer Academic Publishers: Norwell, 1994; pp 1-25.
18. Mutou, T.; Kondo, T.; Shibata, T.; Ojika, M.; Kigoshi, H.; Yamada, K. Tetrahedron Lett. 1996, 37, 7299-7302.
19. R, min) of the authentic amino acids were: L-Pro (11.5); D-Pro (22.2); N-Me-L-Val (13.0); N-Me-D-Val (17.5); N,O-diMe-L-Ser (14.9); N,O-diMe-D-Ser (14.0); N-Me-L-Ile (26.7); N-Me-D-Ile (40.4); N-Me-L-allo-Ile (25.3); and N-Me-D-allo-Ile (39.1). The retention times of the amino acid components in the acid hydrolyzate were 11.5, 13.0, 14.9, and 26.7 min, indicating the presence of L-Pro; N-Me-L-Val; N,O-diMe-L-Ser; and N-Me-L-Ile, respectively.
20. 25D -183° (c 0.11, MeOH).
21. The product showed the same spectral characteristics as 2.
22. Moore, R. E. J. Ind. Microbiol. 1996, 16, 134-143.
23. R 14.2 min, 2.1 mg).
24. The activity of the extract was also due to other cytotoxins, and their structure elucidation is in progress.